158 related articles for article (PubMed ID: 3542268)
21. [The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors].
Liu J; Li M
Zhonghua Fu Chan Ke Za Zhi; 1995 May; 30(5):273-5. PubMed ID: 7648905
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacology of intraperitoneal cisplatin.
Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
[TBL] [Abstract][Full Text] [Related]
23. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
24. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
25. Optimal dosing with carboplatin.
Ozols RF
Semin Oncol; 1989 Apr; 16(2 Suppl 5):14-8. PubMed ID: 2655094
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Verschraegen CF; Kumagai S; Davidson R; Feig B; Mansfield P; Lee SJ; Maclean DS; Hu W; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Oct; 129(10):549-55. PubMed ID: 14513369
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
29. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.
Gore M; Mainwaring P; A'Hern R; MacFarlane V; Slevin M; Harper P; Osborne R; Mansi J; Blake P; Wiltshaw E; Shepherd J
J Clin Oncol; 1998 Jul; 16(7):2426-34. PubMed ID: 9667260
[TBL] [Abstract][Full Text] [Related]
31. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
[TBL] [Abstract][Full Text] [Related]
32. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacological bases of intraperitoneal chemotherapy].
Gladieff L; Chatelut E; Dalenc F; Ferron G
Bull Cancer; 2009 Dec; 96(12):1235-42. PubMed ID: 19923051
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic evaluation of zeniplatin in humans.
DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
36. Can carboplatin replace cisplatin for intraperitoneal use?
Fujiwara K
Int J Gynecol Cancer; 2008; 18 Suppl 1():29-32. PubMed ID: 18336396
[TBL] [Abstract][Full Text] [Related]
37. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
Los G; Mutsaers PH; Ruevekamp M; McVie JG
Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of cisplatin i.p. and carboplatin i.v. with G-CSF in patients with ovarian cancer.
Adachi S; Ito K; Itani Y; Noda T; Shintani M; Kawai S; Beppu K; Ito A; Saito K; Hisanaga H; Fukumoto Y; Tomii Y; Masuda M
Oncol Rep; 1999; 6(2):311-5. PubMed ID: 10022995
[TBL] [Abstract][Full Text] [Related]
40. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]